Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Citius Oncology ( (CTOR) ) just unveiled an update.
On October 27, 2025, Citius Oncology, Inc. held its annual meeting where stockholders approved an amendment to double the shares authorized under the 2024 Omnibus Stock Incentive Plan from 15 million to 30 million, following the Board’s prior approval in September. Additionally, stockholders elected Class I directors Myron Holubiak and Joel Mayersohn for a three-year term and ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. operates in the oncology industry, focusing on developing cancer treatments and therapies.
Average Trading Volume: 293,653
Technical Sentiment Signal: Sell
Current Market Cap: $143.6M
See more insights into CTOR stock on TipRanks’ Stock Analysis page.